Publications by authors named "R Despax"
Article Synopsis
- - The study aimed to evaluate the effectiveness and safety of combining eribulin with bevacizumab as a first-line treatment for HER2-negative metastatic breast cancer, comparing it to previous regimens like paclitaxel.
- - In a clinical trial involving 61 women, the combination treatment resulted in a 32% non-progression rate at one year and a median progression-free survival of 8.3 months, indicating promising results.
- - Adverse effects were reported, with hypertension (39%) and neutropenia (26%) being the most common serious side effects, but overall, the treatment was considered to have an acceptable safety profile with low rates of severe neuropathy.
Background: Expression IV survey evaluated the patients' expectations to a maintenance therapy.
Methods: From January 2015 to March 2016, 401 French patients, in first line or recurrent disease, answered a 24-items anonymous questionnaire. The results were specifically analyzed according to the demographic characteristics and treatment lines.
Background: The results of phase II clinical trials are usually based on response of tumours to new oncolytic agents as evidenced by radiological imaging techniques. In this trial, all claimed responders were reviewed at a specially convened meeting by the peer group of study investigators and a radiologist, independent of the study institutions.
Patients And Methods: One hundred eleven patients with advanced epithelial ovarian cancer who had previously been treated with a platinum based regimen and had subsequently relapsed and who had measurable disease were treated with topotecan at a dose of 1.
Purpose: Topotecan is a topoisomerase I inhibitor with preclinical activity against various tumor types. We conducted a large multicenter phase II study with topotecan in ovarian cancer in patients who had failed to respond to one prior cisplatin-based chemotherapeutic regimen.
Patients And Methods: Topotecan 1.